Microsoft’s AI tools and the Azure cloud platform will be integrated by Tevogen.AI, the AI division of Tevogen Bio, into two key objectives. Credit: T. Schneider/Shutterstock.

Tevogen Bio has expanded its partnership with Microsoft, aiming to further its AI-centred collaboration and advance its predictive precision T-cell targeting technology, PredicTcell.

The strategic move is set to leverage Microsoft’s cloud capabilities, AI and health and life sciences expertise to speed up the detection of target and pre-clinical processes, enhancing Tevogen’s immunotherapy pipeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Microsoft’s advanced AI tools and the Azure cloud platform will be integrated by Tevogen.AI, the AI division of Tevogen Bio, into two key objectives.

The aim is the rapid expansion of the ExacTcell Technology pre-clinical pipeline, based on the trial outcomes of TVGN 489.

By utilising machine learning for critical simulations, the company expects to accelerate the discovery of new targets through the analysis of extensive genomic datasets with enhanced speed and precision.

The partnership is set to develop algorithms for decoding interactions between human leukocyte antigens and T-cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This is anticipated to advance the company’s understanding of immune responses and pave the way for new therapeutic opportunities.

Tevogen Bio chief information officer and Tevogen.AI head Mittul Mehta stated: “As we expand our AI efforts, this broader relationship with Microsoft represents a key milestone in our ongoing journey to revolutionise immunotherapy.

“Through deeper collaboration with Microsoft domain experts, we will further harness the power of AI to bring more precise and personalised treatments to patients at an accelerated pace.”

Tevogen Bio is also exploring human papillomavirus (HPV) treatments through the Microsoft Azure cloud platform and AI tools.

A protein dataset from the HPV genome was curated by the company and is in the process of detecting cytotoxic T-cell (CTL) targets for a trial of Tevogen’s first oncology product candidate, TVGN 920.

With its ExacTcell technology, which trains CTLs to identify certain targets and then expands them, the company is poised to deliver an HPV-specific CTL treatment.

This expanded relationship with Microsoft builds on a previous partnership established in November 2024 to advance the development of an HPV-specific CTL treatment.